CoChat
Sign Up
Cited by 6

Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease

Yang, Fei, Pedersen, Nancy L., Ye, Weimin, Liu, Zhiwei, Norberg, Margareta, Forsgren, Lars, Trolle Lagerros, Ylva, Bellocco, Rino +10 more·2016·International Journal of Epidemiology
DOI 10.1093/ije/dyw294
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ije/dyw294

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is an inverse association between snus use and Parkinson's disease risk (overall pHR = 0.41; 95% CI: 0.28-0.61; current users pHR = 0.38; 95% CI: 0.23-0.63; moderate-heavy amount users pHR = 0.41; 95% CI: 0.19-0.90; long-term users pHR = 0.44; 95% CI: 0.24-0.83).

    “An inverse association between snus use and Parkinson's disease (PD) risk (overall: pHR = 0.41; 95%CI: 0.28-0.61;current users: pHR = 0.38; 95% CI: 0.23-0.63;moderate-heavy amount users: pHR = 0.41; 95% CI: 0.19-0.90and long-term users: pHR = 0.44; 95% CI: 0.24-0.83)(Yang et al. 2017)”

    From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Yang et al. 2017

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

  • In a pooled analysis, there is an inverse association between using snus and Parkinson's disease risk (pHR = 0.41; 95% CI: 0.28-0.61), more evident in current, moderate-heavy amount, and long-term snus users.

    “inverse association between using snus and Parkinson's disease (PD) risk (pooled hazard ratio (pHR) = 0.41; 95% CI: 0.28-0.61),which was more evident in current (pHR = 0.38; 95% CI: 0.23-0.63),moderate-heavy amount (pHR = 0.41; 95% CI: 0.19-0.90)and long-term snus users (pHR = 0.44; 95% CI: 0.24-0.83)(Yang et al. 2017).”

    From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Yang et al. 2017

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011;26(Suppl 1):S1-58.
  2. Noyce AJ, Bestwick JP, Silveira-Moriyama L et al. Meta-analysis of early nonmotor features and risk factors for Parkinson dis- ease. Ann Neurol 2012;72:893-901.
  3. Chen H, Huang X, Guo X et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010;74:878-84.
  4. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord 2012;27:947-57.
  5. O'Reilly EJ, McCullough ML, Chao A et al. Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord 2005;20:1383-84.
  6. Holm H, Jarvis MJ, Russell MA, Feyerabend C. Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology 1992;108:507-11.
  7. Connolly GN, Alpert HR. Trends in the use of cigarettes and other tobacco products, 2000-2007. JAMA 2008;299:2629-30.
  8. Biener L, McCausland K, Curry L, Cullen J. Prevalence of trial of snus products among adult smokers. Am J Public Health 2011;101:1874-76.
  9. Hansson J, Galanti MR, Hergens MP et al. Use of snus and acute myocardial infarction: pooled analysis of eight prospective observational studies. Eur J Epidemiol 2012;27:771-79.
  10. Stegmayr B, Lundberg V, Asplund K. The events registration and survey procedures in the Northern Sweden MONICA Project. Scand J Public Health Suppl 2003;61:9-17.
  11. Hergens MP, Alfredsson L, Bolinder G, Lambe M, Pershagen G, Ye W. Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men. J Intern Med 2007;262:351-59.
  12. Svensson AC, Fredlund P, Laflamme L et al. Cohort profile: The Stockholm Public Health Cohort. Int J Epidemiol 2013;42:1263-72.
  13. Lagerros YT, Bellocco R, Adami HO, Nyren O. Measures of physical activity and their correlates: the Swedish National March Cohort. Eur J Epidemiol 2009;24:161-69.
  14. Pedersen NL, Lichtenstein P, Svedberg P. The Swedish Twin Registry in the third millennium. Twin Res 2002;5:427-32.
  15. Alfredsson L, Hammar N, Fransson E et al. Job strain and major risk factors for coronary heart disease among employed males and females in a Swedish study on work, lipids and fibrinogen. Scand J Work Environ Health 2002;28:238-48.
  16. Ludvigsson JF, Andersson E, Ekbom A et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
  17. Johansson LA, Westerling R. Comparing Swedish hospital discharge records with death certificates: implications for mor- tality statistics. Int J Epidemiol 2000;29:495-502.
  18. Feldman AL, Johansson AL, Gatz M et al. Accuracy and sensitiv- ity of Parkinsonian disorder diagnoses in two Swedish national health registers. Neuroepidemiology 2012;38:186-93.
  19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
  20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta- analysis. Stat Med 2002;21:1539-58.
  21. Hawkes CH. The prodromal phase of sporadic Parkinson's dis- ease: does it exist and if so how long is it? Mov Disord 2008;23:1799-807.
  22. Therneau TM, Grambsch PM. Modelling Survival Data: Extending the Cox Model. New York, NY: Springer, 2000.
  23. Hong DP, Fink AL, Uversky VN. Smoking and Parkinson's dis- ease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta 2009;1794:282-90.
  24. Ward RJ, Lallemand F, de Witte P, Dexter DT. Neurochemical pathways involved in the protective effects of nicotine and etha- nol in preventing the development of Parkinson's disease: poten- tial targets for the development of new therapeutic agents. Prog Neurobiol 2008;85:135-47.
  25. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron charac- teristics and nicotinic properties in the striatum. J Neurobiol 2002;53:590-605.
  26. Quik M, Wonnacott S. alpha6beta2* and alpha4beta2* nico- tinic acetylcholine receptors as drug targets for Parkinson's dis- ease. Pharmacol Rev 2011;63:938-66.
  27. Quik M, Parameswaran N, McCallum SE et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem 2006;98:1866-75.
  28. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, Di Monte D. Nicotine reduces levodopa-induced dyskinesias in le- sioned monkeys. Ann Neurol 2007;62:588-96.
  29. Holmes AD, Copland DA, Silburn PA, Chenery HJ. Acute nico- tine enhances strategy-based semantic processing in Parkinson's disease. Int J Neuropsychopharmacol 2011;14:877-85.
  30. Norberg M, Malmberg G, Ng N, Brostrom G. Who is using snus? -Time trends, socioeconomic and geographic characteris- tics of snus users in the ageing Swedish population. BMC Public Health 2011;11:929.
  31. Hershey LA, Perlmutter JS. Smoking and Parkinson disease: where there is smoke there may not be fire. Neurology 2014;83:1392-93.
  32. Ritz B, Lee PC, Lassen CF, Arah OA. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 2014;83:1396-402.
  33. Thacker EL, O'Reilly EJ, Weisskopf MG et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007;68:764-68.
  34. Castagnoli K, Murugesan T. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links? Neurotoxicology 2004;25:279-91.

Cited by

Sorted by citations

Authors
Yang, F., Pedersen, N. L., Ye, W., Liu, Z., Norberg, M., Forsgren, L., Trolle Lagerros, Y., Bellocco, R., Alfredsson, L., Knutsson, A., Jansson, J.-H., Wennberg, P., Galanti, M. R., Lager, A. C. J., Araghi, M., Lundberg, M., Magnusson, C., & Wirdefeldt, K.
Venue
International Journal of Epidemiology
Publisher
Oxford University Press (OUP)
Published
2016-12-10
Pages
dyw294
ISSN
  • 0300-5771
  • 1464-3685
DOI
10.1093/ije/dyw294
Cited by
6
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review